DK1165115T3 - Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer - Google Patents

Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer

Info

Publication number
DK1165115T3
DK1165115T3 DK00916545T DK00916545T DK1165115T3 DK 1165115 T3 DK1165115 T3 DK 1165115T3 DK 00916545 T DK00916545 T DK 00916545T DK 00916545 T DK00916545 T DK 00916545T DK 1165115 T3 DK1165115 T3 DK 1165115T3
Authority
DK
Denmark
Prior art keywords
vascular permeability
modulation
tie2 receptor
receptor activators
mammal
Prior art date
Application number
DK00916545T
Other languages
English (en)
Inventor
Chitra Suri
George D Yancopoulos
Donald Mcdonald
Gavin Thurston
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/286,033 external-priority patent/US6455035B1/en
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK1165115T3 publication Critical patent/DK1165115T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00916545T 1999-03-26 2000-03-20 Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer DK1165115T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12653999P 1999-03-26 1999-03-26
US09/286,033 US6455035B1 (en) 1999-03-26 1999-04-05 Angiopoietins and methods of use thereof
PCT/US2000/007336 WO2000057901A1 (en) 1999-03-26 2000-03-20 Modulation of vascular permeability by means of tie2 receptor activators

Publications (1)

Publication Number Publication Date
DK1165115T3 true DK1165115T3 (da) 2003-09-22

Family

ID=26824785

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00916545T DK1165115T3 (da) 1999-03-26 2000-03-20 Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer

Country Status (14)

Country Link
EP (1) EP1165115B1 (da)
JP (1) JP2002540165A (da)
AT (1) ATE241380T1 (da)
AU (1) AU769198B2 (da)
CA (1) CA2368670C (da)
DE (1) DE60003011T2 (da)
DK (1) DK1165115T3 (da)
ES (1) ES2199804T3 (da)
HK (1) HK1043537A1 (da)
IL (2) IL145504A0 (da)
NO (1) NO329198B1 (da)
NZ (1) NZ514434A (da)
PT (1) PT1165115E (da)
WO (1) WO2000057901A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022176A1 (en) 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
EP2518083A3 (en) * 2005-12-15 2012-12-05 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
CA2838846C (en) * 2009-01-12 2018-06-19 Aerpio Therapeutics Inc. Compositions and methods for treating brain edema
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
AU2012323849B2 (en) 2011-10-13 2017-04-20 EyePoint, Inc. Treatment of ocular disease
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6277318A (ja) * 1985-10-01 1987-04-09 Eisai Co Ltd 熱傷治療剤
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
CA2263890C (en) * 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies

Also Published As

Publication number Publication date
CA2368670A1 (en) 2000-10-05
NO20014673L (no) 2001-11-22
IL145504A0 (en) 2002-06-30
DE60003011D1 (de) 2003-07-03
JP2002540165A (ja) 2002-11-26
EP1165115A1 (en) 2002-01-02
CA2368670C (en) 2012-06-05
DE60003011T2 (de) 2004-04-08
NO329198B1 (no) 2010-09-13
NZ514434A (en) 2003-11-28
EP1165115B1 (en) 2003-05-28
AU769198B2 (en) 2004-01-22
ATE241380T1 (de) 2003-06-15
IL145504A (en) 2008-08-07
PT1165115E (pt) 2003-10-31
NO20014673D0 (no) 2001-09-26
HK1043537A1 (zh) 2002-09-20
WO2000057901A1 (en) 2000-10-05
AU3763400A (en) 2000-10-16
ES2199804T3 (es) 2004-03-01

Similar Documents

Publication Publication Date Title
NO20014673D0 (no) Modulering av vaskul¶r permeabilitet ved hjelp av TIE2- reseptoraktivatorer
DE59911670D1 (de) Glutamin-Thiazolidide und -Pyrrolidide sowie ihre Verwendung als Dipeptidylpeptidase IV Inhibitoren
TR200000782T2 (tr) Resorsinol türevleri.
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
DK2412368T3 (da) Sammensætning til behandling af ar
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
ID19242A (id) Pirometer untuk gas dapur api
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DK1109571T3 (da) Fremgangsmåde til behandling af saltafhængig hypertension
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
TR200001290T2 (tr) Estrojen mahrumiyet sendromunu tedavi etmek için yararlı 2-aril-3-aroilbenzo(b) tiofenler.
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
DE60116557D1 (de) Karl-Fischer-Reagenz
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
BR0114884A (pt) Compostos calcilìticos
DE50003452D1 (de) Wässrige zusammensetzung zur filzfreiausrüstung von wolle
DE50109698D1 (de) N-heteroarylmethyl-m-phenylendiamin-derivate enthaltende färbemittel für keratinfasern sowie neue n-heteroarylmethyl-m-phenylendiamin-derivate
PT1156999E (pt) Metodo para a preparacao de um beta-aminoester quiral
NZ331678A (en) Method of checking integrity of modified atmosphere package by placing gas indicator between package and liner
DE69631500D1 (de) Inhibitor des Hepatozytwachstumsfaktoraktivators
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung